

Atezolizumab IMbrave150

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



Atezolizumab IMbrave150

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy

Experimental Arm: Atezolizumab + Bevacizumab

Control Arm: Sorafenib

